

Ref: FOI/GS/ID 8881

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

28 February 2024

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Breast cancer.

*You asked: All questions are shown as received by the Trust.*

*Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:*

- a. Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- b. Abemaciclib + Fulvestrant*
- c. Alpelisib + Fulvestrant*
- d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent*
- e. Atezolizumab + Nab-paclitaxel/Paclitaxel*
- f. Capecitabine as a single agent*
- g. Eribulin as a single agent or in combination*
- h. Everolimus + Exemestane*
- i. Fulvestrant as a single agent*
- j. Lapatinib*
- k. Neratinib*
- l. Parp Inhibitors (Olaparib/Talazoparib)*
- m. Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- n. Palbociclib + Fulvestrant*
- o. Pembrolizumab*
- p. Platinum (e.g. carboplatin or cisplatin) as a single agent*
- q. Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- r. Ribociclib + Fulvestrant*
- s. Sacituzumab Govitecan*
- t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent*
- u. Taxane and/or Anthracycline in combination*
- v. Trastuzumab as a single agent or in combination*
- w. Trastuzumab emtansine*

x. *Transtuzumab deruxtecan*

y. *Any other active systemic anti-cancer therapy*

Q2. *Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.*

Trust response:

Q1.

a.	48
b.	0
c.	0
d.	1
e.	6
f.	26
g.	3
h.	5
i.	2
j.	0
k.	0
l.	0
m.	58
n.	24
o.	4
p.	2
q.	21
r.	4
s.	2
t.	19
u.	53
v.	98
w.	10
x.	1
y.	5

Q2.

IRAS Number	Project Short title	Project site status	Recruited	CTIMP
1003524	heredERA	Open	0	Yes
1007071	INAVO121	Open	0	No
260722	MEDICI	Open	39	No
292122	HER2-RADiCAL	Open	3	Yes
1003435	persevERA Breast Cancer	Closed to recruitment - in follow up	2	Yes
126381	PAKT	Closed to recruitment - in follow up	3	Yes
127164	NCRN - 2372 - PD-0332991 + Letrozole in ER+ HER2- advanced BC	Closed to recruitment - in follow up	5	Yes
134352	MAMMO-50	Closed to recruitment - in follow up	64	No
137785	POSNOC.	Closed to recruitment - in follow up	7	No

142447	UNIRAD	Closed to recruitment - in follow up	2	Yes
165983	CANC - 3831 MBC - disease registry study Esther	Closed to recruitment - in follow up	11	No
187103	plasmaMATCH	Closed to recruitment - in follow up	14	Yes
200813	PALbociclib CoLLaborative Adjuvant Study	Closed to recruitment - in follow up	12	Yes
259240	PALMIRA	Closed to recruitment - in follow up	15	Yes
290151	Phase III study of Niraparib vs placebo in patients with Breast Cancer	Closed to recruitment - in follow up	1	Yes
304561	IMPARTER:4	Closed to recruitment - in follow up	2	No
7380	ARTemis	Closed to recruitment - in follow up	21	Yes
	Persephone	Closed to recruitment - in follow up	57	Yes